Recursion Pharmaceuticals Inc (NASDAQ: RXRX) started the day on Thursday, with a price decrease of -6.56% at $6.55, before settling in for the price of $7.01 at the close. Taking a more long-term approach, RXRX posted a 52-week range of $4.97-$15.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 132.77%. Meanwhile, its Annual Earning per share during the time was -43.41%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 1.11%. This publicly-traded company’s shares outstanding now amounts to $291.36 million, simultaneously with a float of $226.81 million. The organization now has a market capitalization sitting at $1.91 billion. At the time of writing, stock’s 50-day Moving Average stood at $6.68, while the 200-day Moving Average is $8.80.
Recursion Pharmaceuticals Inc (RXRX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Recursion Pharmaceuticals Inc’s current insider ownership accounts for 22.15%, in contrast to 74.81% institutional ownership. According to the most recent insider trade that took place on Oct 15 ’24, this organization’s Director sold 11,447 shares at the rate of 6.67, making the entire transaction reach 76,326 in total value, affecting insider ownership by 7,089,007.
Recursion Pharmaceuticals Inc (RXRX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
Recursion Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 1.11% and is forecasted to reach -1.72 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 12.00% through the next 5 years, which can be compared against the -43.41% growth it accomplished over the previous five years trading on the market.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Let’s observe the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). It’s Quick Ratio in the last reported quarter now stands at 6.07. The Stock has managed to achieve an average true range (ATR) of 0.38. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 38.45.
In the same vein, RXRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.62, a figure that is expected to reach -0.33 in the next quarter, and analysts are predicting that it will be -1.72 at the market close of one year from today.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
If we take a close look at the recent performances of Recursion Pharmaceuticals Inc (NASDAQ: RXRX), its last 5-days Average volume was 4.19 million that shows plunge from its year to date volume of 5.78 million. During the previous 9 days, stock’s Stochastic %D was recorded 76.85% While, its Average True Range was 0.38.
Raw Stochastic average of Recursion Pharmaceuticals Inc (RXRX) in the period of the previous 100 days is set at 16.20%, which indicates a major fall in contrast to 52.17% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 65.18% that was lower than 74.77% volatility it exhibited in the past 100-days period.
